Tags

Type your tag names separated by a space and hit enter

The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE).
J Exp Clin Cancer Res. 2007 Sep; 26(3):307-12.JE

Abstract

Current management of bone metastases involves a multimodal approach. Aminobisphosphonates (BPs) are a valid weapon in the treatment of skeletal localization of tumour disease. Patients with bone metastases from breast and lung cancer were enrolled in order to evaluate the impact of the addition of bisphosphonates therapy to standard treatments in terms of (i) pain control, (ii) quality of life (QoL) and (iii) toxicity and to evaluate (iv) any relations between clinical activity and the occurrence of SREs. A total of 60 patients were included in the study. Median age was 76 years (range 40-83). The majority of patients were treated with chemotherapy or hormonal therapy. All patients received zoledronic acid (ZOL) (4 mg) every 3-4 weeks for at least 3 cycles. No significant improvement in Performance Status of patients after 12 cycles of ZOL (p = 0.1672) was recorded. A statistically significant early and long-lasting amelioration of both pain, narcotic scores and QoL was found. Twenty-one patients (48%) experienced at least one SRE during the study. The most common SRE was radiation to bone (30% of patients). An inverse correlation between bone tumour response and SREs was also found (p = 0.019). ZOL addition induces a clinical benefit and improves QoL of patients with bone metastases. Moreover, the occurrence of bone clinical response is related to a reduced risk of SREs.

Authors+Show Affiliations

Facchini G
Medical Oncology Division B, National Cancer Institute, Naples, Italy.
Caraglia M
No affiliation info available
Santini D
No affiliation info available
Nasti G
No affiliation info available
Ottaiano A
No affiliation info available
Striano S
No affiliation info available
Maiolino P
No affiliation info available
Ruberto M
No affiliation info available
Fiore F
No affiliation info available
Tonini G
No affiliation info available
Budillon A
No affiliation info available
Iaffaioli RV
No affiliation info available
Zeppetella GL
No affiliation info available

MeSH

AdultAgedAged, 80 and overBone Density Conservation AgentsBone NeoplasmsBreast NeoplasmsDiphosphonatesFemaleHumansImidazolesLung NeoplasmsMaleMiddle AgedMusculoskeletal SystemQuality of LifeZoledronic Acid

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

17987788

Citation

Facchini, G, et al. "The Clinical Response On Bone Metastasis From Breast and Lung Cancer During Treatment With Zoledronic Acid Is Inversely Correlated to Skeletal Related Events (SRE)." Journal of Experimental & Clinical Cancer Research : CR, vol. 26, no. 3, 2007, pp. 307-12.
Facchini G, Caraglia M, Santini D, et al. The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE). J Exp Clin Cancer Res. 2007;26(3):307-12.
Facchini, G., Caraglia, M., Santini, D., Nasti, G., Ottaiano, A., Striano, S., Maiolino, P., Ruberto, M., Fiore, F., Tonini, G., Budillon, A., Iaffaioli, R. V., & Zeppetella, G. L. (2007). The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE). Journal of Experimental & Clinical Cancer Research : CR, 26(3), 307-12.
Facchini G, et al. The Clinical Response On Bone Metastasis From Breast and Lung Cancer During Treatment With Zoledronic Acid Is Inversely Correlated to Skeletal Related Events (SRE). J Exp Clin Cancer Res. 2007;26(3):307-12. PubMed PMID: 17987788.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE). AU - Facchini,G, AU - Caraglia,M, AU - Santini,D, AU - Nasti,G, AU - Ottaiano,A, AU - Striano,S, AU - Maiolino,P, AU - Ruberto,M, AU - Fiore,F, AU - Tonini,G, AU - Budillon,A, AU - Iaffaioli,R V, AU - Zeppetella,G L, PY - 2007/11/9/pubmed PY - 2007/12/27/medline PY - 2007/11/9/entrez SP - 307 EP - 12 JF - Journal of experimental & clinical cancer research : CR JO - J Exp Clin Cancer Res VL - 26 IS - 3 N2 - Current management of bone metastases involves a multimodal approach. Aminobisphosphonates (BPs) are a valid weapon in the treatment of skeletal localization of tumour disease. Patients with bone metastases from breast and lung cancer were enrolled in order to evaluate the impact of the addition of bisphosphonates therapy to standard treatments in terms of (i) pain control, (ii) quality of life (QoL) and (iii) toxicity and to evaluate (iv) any relations between clinical activity and the occurrence of SREs. A total of 60 patients were included in the study. Median age was 76 years (range 40-83). The majority of patients were treated with chemotherapy or hormonal therapy. All patients received zoledronic acid (ZOL) (4 mg) every 3-4 weeks for at least 3 cycles. No significant improvement in Performance Status of patients after 12 cycles of ZOL (p = 0.1672) was recorded. A statistically significant early and long-lasting amelioration of both pain, narcotic scores and QoL was found. Twenty-one patients (48%) experienced at least one SRE during the study. The most common SRE was radiation to bone (30% of patients). An inverse correlation between bone tumour response and SREs was also found (p = 0.019). ZOL addition induces a clinical benefit and improves QoL of patients with bone metastases. Moreover, the occurrence of bone clinical response is related to a reduced risk of SREs. SN - 0392-9078 UR - https://www.unboundmedicine.com/medline/citation/17987788/The_clinical_response_on_bone_metastasis_from_breast_and_lung_cancer_during_treatment_with_zoledronic_acid_is_inversely_correlated_to_skeletal_related_events__SRE__ DB - PRIME DP - Unbound Medicine ER -
Grapherence [↓11]

Related Citations

More